Circulating exosomal miR-363-5p inhibits lymph node metastasis by downregulating PDGFB and serves as a potential noninvasive biomarker for breast cancer
Quick Facts
- Publication title: Circulating exosomal miR-363-5p inhibits lymph node metastasis by downregulating PDGFB and serves as a potential noninvasive biomarker for breast cancer
- Journal: Mol Oncol
- Year: 2021
- DOI: 10.1002/1878-0261.13029
- PMID/PMCID: 34058065; PMC8410538
Research overview
We identified an exosomal miRNA, miR-363-5p, that was significantly downregulated in exosomes from plasma of BC patients with LN metastasis which exhibited a consistent decreasing trend in tissue samples from multiple independent datasets. Our study revealed, for the first time, plasma exosomal miR-363-5p plays a tumor suppressor role in BC and has the potential for noninvasive LN staging and prognosis prediction of BC.
Key findings
Sentinel lymph node (LN) biopsy is currently the standard procedure for clinical LN-negative breast cancer (BC) patients but it is prone to false-negative results and complications.
Thus, an accurate noninvasive approach for LN staging is urgently needed in clinical practice.
Here, circulating exosomal microRNA (miRNA) expression profiles in peripheral blood from BC patients and age-matched healthy women were obtained and analyzed.
We identified an exosomal miRNA, miR-363-5p, that was significantly downregulated in exosomes from plasma of BC patients with LN metastasis which exhibited a consistent decreasing trend in tissue samples from multiple independent datasets.
Echo Biotech Role
Echo Biotech contributed miRNA profiling/sequencing and bioinformatic analysis.
Related platforms: Exoomics®
Related services and capabilities: EV miRNA Profiling / Sequencing
References
Original publication: Circulating exosomal miR-363-5p inhibits lymph node metastasis by downregulating PDGFB and serves as a potential noninvasive biomarker for breast cancer Mol Oncol. 2021. DOI: 10.1002/1878-0261.13029. PMID/PMCID: 34058065; PMC8410538.